Congratulations to WashU Ophthalmology Resident, Matt Elitt, MD, PhD and Case Western Reserve’s Tesar Lab colleagues, on the advancement of ION356 to a phase I human clinical trial.
Dr. Elitt’s doctoral research published in Nature demonstrated a novel method to pharmacologically target the pathology of Pelizaeus-Merzbacher disease (PMD), representing the first potential treatment option for patients and their families.
PMD is a lethal pediatric disorder that presents with severe neurological deficits, including nystagmus, optic atrophy, motor impairment, and cognitive disability. You can read more about this trial from the PMD Foundation’s announcement.
Dr. Elitt completed his doctoral studies in the Tesar Lab at the Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, located in Cleveland, OH.